ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Sakar Healthcare Q1 FY27 results show strong oncology pivot with 38% YoY revenue growth and 120% profit jump.
Sakar Healthcare reported strong Q1FY27 consolidated results with 38% Revenue growth and 120% PAT growth, driven by its vertically integrated oncology business and expansion into regulated markets.
Sakar Healthcare Q4 FY26 revenue grew 42% YoY to ₹71.1cr with 37% EBITDA margins. Strategy focuses on transforming into a pure-play oncology exporter via its EU GMP facility.
Sakar Healthcare Q4FY26 presentation highlights a strategic shift toward high-margin oncology, leveraging a new EU-GMP integrated API-FDF facility in Bavla to drive specialized global healthcare solutions.